DelMar Pharmaceuticals of Vancouver, British Columbia recently appointed two individuals to its board of directors, in alignment with its mission both to strengthen the board and to allow for expansion of its current executive’s scope.
Saiid Zarrabian joined the firm’s board of directors, while Dr. Erich Mohr was elected as chairman. DelMar President and CEO Jeffrey Bacha had also served as chairman since 2010, but now the company seeks to diversify the board to let Bacha specialize more in daily operational functions as CEO.
“DelMar has reached a point in its corporate and clinical maturation where we are excited to have access to Saiid's operational expertise and experience," Bacha said. "Furthermore, I am very pleased that Erich has agreed to take on the role of chairman as his executive leadership, clinical development and company building experience will greatly benefit DelMar as we continue the next phase of our growth.”
Zarrabian brings over three decades of executive and board experience to his new post. He is an adviser to Redline Capital Partners S.A., an investment firm based in Luxembourg. Previously, he led a division at Intrexon Corp., specializing in synthetic biology; and he has extensive prior board experience.
Mohr, a director at DelMar for over two years, has spent close to 20 years in leadership roles for biotechnology enterprises. Currently he serves as chairman and CEO of MedGenesis Therapeutix Inc., a private firm focused on addressing therapies for neurological diseases. Additionally, he has served in academia for over 30 years at Canadian and U.S. universities.